Gain Therapeutics Inc.
GANX | NASDAQ
$1.95
+$0.11 (+5.98%)
At close: Sep 22, 2026, 4:00 PM ET
$1.95
$0 (0.00%)
After-hours:
Sep 22, 2026, 7:30 PM ET
Market Data
Market Cap $78.48M
Enterprise Value $65.67M
Beta 0.21
Average Volume 743.87K
Shares Outstanding (Diluted) 42.88M
Shares Change YoY 41.32%
Institutional Ownership 19.41%
Exchange NASDAQ
ISIN US36269B1052
Price Performance
Price Change 1M -8.0%
Price Change 3M 4.0%
Price Change 6M -6.1%
Price Change YTD -42.1%
Price Change 1Y 5.8%
Price Change 3Y -44.9%
Price Change 5Y -75.2%
1M CAGR (ann.) 1.1%
1Y CAGR (ann.) 8.2%
5Y CAGR (ann.) -26.3%
All-Time CAGR -27.9%
Valuation
PE Ratio -3.68
Forward PE N/A
PEG Ratio -0.13
Forward PEG -0.12
PS Ratio N/A
Forward PS 348.80
PB Ratio 6.95
P/FCF Ratio -4.14
P/Adj. FCF Ratio -3.78
P/OCF Ratio -4.18
EV/Sales N/A
EV/EBIT -3.42
EV/EBITDA -3.44
EV/FCF -3.46
Earnings Yield -27.2%
FCF Yield -24.1%
Adj. FCF Yield -26.5%
Financial Health
Net Cash $13.08M
Total Debt $266.19K
Cash & Short-Term Investments $13.08M
Total Assets $15.42M
Current Ratio 4.36
Quick Ratio 4.36
Debt / Equity Ratio 0.05
Debt / EBITDA -0.01
Debt / FCF -0.01
OCF / Debt -71.20
Interest Coverage 0.00
Altman Z-Score -1.94
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin 0.0%
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue 0.0%
SBC Impact (per share) -9.7%
Returns
Return on Assets -130.4%
Return on Equity -161.6%
Return on Invested Capital -157.8%
Return on Capital Employed -160.9%
Return on Tangible Assets -130.4%
Historical Growth (CAGR)
Revenue CAGR 3Y -150.0%
Revenue CAGR 5Y -89.6%
Revenue CAGR 10Y N/A
EPS CAGR 3Y 48.8%
EPS CAGR 5Y 26.3%
EPS CAGR 10Y N/A
FCF CAGR 3Y 0.1%
FCF CAGR 5Y -6.9%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 8
EPS Growth Next 3Y 54.7%
Revenue Growth Next 3Y N/A
Earnings Date Nov 10, 2026
EPS Estimate (next Q) -$0.13
EPS Growth Est (next Q) -13.3%
Revenue Est (next Q) $33.33K
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $7.80
Price Target Upside 323.9%
Cash Flow
Operating Cash Flow $-18.95M
Free Cash Flow $-18.95M
Adj. Free Cash Flow $-20.78M
FCF Per Share -$0.44
OCF Per Share -$0.44
OCF/S Ratio 0.0%
Income Statement
Revenue $0
Gross Profit $0
Operating Income $-19.29M
EBITDA $-19.1M
Net Income $-20.11M
EPS (Diluted) -$0.50
Revenue / Employee N/A
Profit / Employee $-957.44K
Employees 21
Add to Watchlist
Select watchlists to add or remove GANX